SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial
Allergy · 2025
DOI: 10.1111/all.70073 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Allergy, 2025. Verfasst von Graham Roberts und 5 weiteren Autor:innen. Beteiligte Einrichtung: The David Hide Asthma and Allergy Centre, St Mary's Hospital, Newport, Isle of Wight, UK. Hauptthemen laut MEDLINE: Asthma, Sublingual Immunotherapy, Pyroglyphidae, Antigens, Dermatophagoides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ALK-Abelló A/S.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
In children, house dust mite (HDM) sensitisation is a contributing factor for developing allergic asthma. HDM allergen immunotherapy has demonstrated efficacy and safety in adults with allergic asthma; however, evidence for its use in children is limited. MT‐11 evaluated the efficacy and safety of the SQ HDM sublingual immunotherapy (SLIT) tablet in children (5–17 years) with HDM allergic asthma.
Methods
This phase III, randomised, double‐blind, placebo‐controlled trial randomised 533 children with a recent history of asthma exacerbations, despite treatment with inhaled corticosteroids and/or long‐acting beta‐agonists, to daily treatment with SQ HDM SLIT‐tablet or placebo for 24–30 months. The primary endpoint was the annualised rate of clinically relevant asthma exacerbations. Adverse events (AEs) were reported throughout the trial.
Results
The rate ratio for the annualised rate of clinically relevant asthma exacerbations was 0.89 (95% CI: 0.60, 1.31), in favour of the SQ HDM‐SLIT tablet; superiority over placebo was not established. Most treatment‐related AEs (TRAEs) were of mild or moderate severity, and few subjects discontinued due to TRAEs (< 2%). The most common TRAEs were local application site reactions (oral pruritus, throat irritation, ear pruritus, and upper abdominal pain). There was no increased incidence of asthma‐related events, and no anaphylaxis or adrenaline use in the SQ HDM SLIT‐tablet group.
Conclusion
As a result of the coronavirus disease 2019 pandemic, asthma exacerbation rates were much lower than expected, contributing to the primary endpoint not being met. The SQ HDM SLIT‐tablet was well tolerated in a paediatric population with inadequately controlled HDM allergic asthma. Trial Registration Clinicaltrials.gov identifier: NCT03654976; EudraCT number: 2016‐004363‐39
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The David Hide Asthma and Allergy Centre, St Mary's Hospital, Newport, Isle of Wight, UK.
- NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
- University of Southampton Faculty of Medicine and University Hospital Southampton, Southampton, UK.
- Unité d'Allergologie, Hôpital Américain de Paris, Neuilly sur Seine, France.
- Sorbonne Université, Paris, France.
- CRESS, Inserm, INRAE, HERA Team, Université Paris Cité, Paris, France.
ORCID-Profile: Graham Roberts, Jocelyne Just, Ole Holm Hels, Andrzej Emeryk, Carmen Vidal
Förderung
- ALK-Abelló A/S
Zitieren
APA
Roberts, G., Just, J., Nolte, H., Hels, O. H., Emeryk, A., & Vidal, C. (2025). SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial. Allergy. https://doi.org/10.1111/all.70073
Vancouver
Roberts G, Just J, Nolte H, Hels OH, Emeryk A, Vidal C. SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial. Allergy. 2025. doi:10.1111/all.70073
BibTeX
@article{Roberts2025,
author = {Roberts, Graham and Just, Jocelyne and Nolte, Hendrik and Hels, Ole Holm and Emeryk, Andrzej and Vidal, Carmen},
title = {SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.70073}
}
EUVIMED